title: Pulmonary complications in survivors of childhood hematological malignancies: single-center experience.
abstract: Children treated for cancer face the risk of complications later in life, including pulmonary dysfunction. The objective of this study was to evaluate frequency and severity of pulmonary complications in survivors of childhood leukemia and lymphoma treated with chemotherapy alone or combined with radiotherapy. Seventy cancer survivors of hematological malignancies were evaluated for pulmonary complications through history taking, chest examination, high-resolution computed tomography (HRCT) chest, and pulmonary function testing (PFTs). Although most survivors were not clinically compromised, the spectrum of impaired PFTs included obstructive pattern (14.3%), restrictive pattern (5.7%), and mixed pattern (20%). Significant pulmonary dysfunction was seen in children older than 10 years of age (P = .003), and in patients treated with combined chemotherapy and radiotherapy (72.7%) compared with those treated with chemotherapy alone (25%) (P = .001). Cumulative dose of bleomycin was significantly associated with abnormal PFTs (P = .04). Multivariate analysis revealed methotrexate therapy as significant predictor of abnormal PFTs (P = .002). Male patients who received combined therapy showed higher frequency of restrictive, obstructive lung disease, abnormal respiratory reactance, and peripheral airway disease (P = .007, P = .04, P = .002, P = .003, P = .05, respectively). Those with abnormal CT findings (n = 14) had lower forced vital capacity (FVC%), forced expiratory volume in 1 second (FEV(1)%), and peak expiratory flow (PEF%) when compared to cases with normal CT (P = .001, P < 0.001, P = .001, respectively). Subclinical pulmonary function abnormalities are found in survivors of childhood hematological malignancies previously treated and off therapy. Pulmonary dysfunction is more evident with combined chemotherapy and radiotherapy, bleomycin, and methotrexate are the most incriminated chemotherapeutic agents, and males are at higher risk than females; therefore a specific and extended follow-up is warranted.
authors: Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt. azazaghloul@yahoo.com
authors: Azza Abdel Gawad
authors: AA
authors: Tantawy
authors: Nancy
authors: N
authors: Elbarbary
authors: Asmaa
authors: A
authors: Ahmed
authors: Nancy Abdraoaf
authors: NA
authors: Mohamed
authors: Sahar
authors: S
authors: Ezz-Elarab
mesh_terms: D000293:Adolescent; D000328:Adult; D002097:C-Reactive Protein / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008171:Lung Diseases / Q000209:etiology*; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D017741:Survivors; D014057:Tomography, X-Ray Computed; D014797:Vital Capacity
chemical_list: D002097:C-Reactive Protein; D008727:Methotrexate